PHOSLOCK ENVIRONMENTAL TECHN(PET.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

PET.AU PHOSLOCK ENVIRONMENTAL TECHN

Halted 03-24 16:12:00 AEDT

0.03

+0.00

0.00%

High0.03	Low0.03	Vol0.00
Open0.03	D1 Closing0.03	Amplitude0.00%
Mkt Cap15.61M	Tradable Cap15.50M	Total Shares624.39M
T/O0.00	T/O Rate0.00%	Tradable Shares619.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PET.AU","market":"AU","secType":"STK","nameCN":"PHOSLOCK ENVIRONMENTAL TECHN","latestPrice":0.025,"timestamp":1742793120000,"preClose":0.025,"halted":3,"volume":0,"delay":0,"nameEN":"PHOSLOCK ENVIRONMENTAL TECHN","floatShares":619978191,"shares":624390509,"eps":-0.015899,"marketStatus":"Halted","change":0,"latestTime":"03-24 16:12:00 AEDT","open":0.025,"high":0.025,"low":0.025,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.015899,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1742857200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.025,"openAndCloseTimeList":[[1742770800000,1742792400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/PET.AU","defaultTab":"news","newsList":[{"id":"2522752706","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2522752706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522752706?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 02:37","pubTimestamp":1742841460,"startTime":"0","endTime":"0","summary":"23andMe  filed for Chapter 11 bankruptcy protection to help facilitate a potential sale, while Anne Wojcicki resigned as chief executive, less than a month after she attempted to acquire the genetic testing firm.Shares slumped 57%, with intraday trading volume of over 5.5 million against a daily average of about 292,000.TransCode Therapeutics  said Sunday it agreed to sell 10.25 million shares and warrants to buy up to 10.25 million shares at $0.98 per share and warrant to raise some $10 million.Shares sank 38% as intraday trading volume rose to over 15.5 million from a daily average of about 6.36 million.Wag!Group  said Monday its board is advancing a review of \"strategic alternatives to identify opportunities to maximize value for shareholders, including potential investments, strategic partnerships, sale, merger, or other strategic transactions involving the company or its assets.\"Shares slid 22% as intraday trading volume rose to over 1.3 million from a daily average of about 665,0","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PET.AU","BK4192","RNAZ","BK4121","BK7047","PET","BK4139","BK4539","BK4196","ME"],"gpt_icon":1},{"id":"2520842426","title":"Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2520842426","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520842426?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 05:53","pubTimestamp":1742248380,"startTime":"0","endTime":"0","summary":"MELBOURNE,Australia andPORTO ALEGRE,Brazil, March 18, 2025  -- Telix Pharmaceuticals Limited  today announces that the Brazilian Health Regulatory Agency  has approved Illuccix  the Company’s lead prostate cancer imaging agent. Illuccix is the first and only PSMA-PET1 prostate cancer imaging agent to receive full regulatory approval in Brazil.Illuccix, after radiolabeling with 68Ga, is a radioactive diagnostic agent indicated for positron emission tomography  of prostate-specific membrane antigen  positive lesions in men with prostate cancer:. With suspected metastasis who are candidates for definitive initial therapy treatment, and. With suspected recurrence based on an elevated specific antigen  level in the serum.PSMA-PET is a diagnostic technology demonstrated to detect advanced prostate cancer. ANVISA becomes the latest regulatory body worldwide to approve Illuccix3, which is already commercially available in Australia, Canada, New Zealand and the United States, and has recently b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illuccix-approved-prostate-cancer-imaging-215300352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4533","BK4588","TGA.AU","ASX.AU","XJO.AU","PET.AU","BK7067","BK7047","BK4217","SEC.AU","BK4526","DCP","EEA","TLX.AU","BK4141","BK4233","BK7039","UK","BK4213","BK4192","BK4144","ASX","BK4084","TLX","BK4543","BK4139","BK4528","TGA","BK7001","BK4585","BK4205","XAO.AU","PSA","PET","XKO.AU"],"gpt_icon":0},{"id":"2518420417","title":"Rapport Therapeutics advancing RAP-219 amid $20M Q4 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2518420417","media":"Grafa","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518420417?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 21:57","pubTimestamp":1741701475,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics , a biotechnology company focused on neurological and psychiatric disorders, today released its fourth quarter and full-year 2024 financial results alongside a significant business update, highlighting promising clinical progress with its lead drug candidate, RAP-219.The company announced that results from its positron emission tomography  and second multiple ascending dose  trials support RAP-219's potential as a transformative treatment for epilepsy and other central nervous system  disorders.Rapport Therapeutics is currently advancing RAP-219 in a Phase 2a trial for refractory focal epilepsy, with topline results anticipated in the third quarter of 2025.Expanding its clinical pipeline, Rapport Therapeutics also revealed plans to initiate a Phase 2a trial of RAP-219 in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027.Despite the increased spending, Rapport Therapeutics maintains a strong financial p","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-rapport-therapeutics-advancing-rap-219-amid--20m-q4-loss-395052-638772982753484407.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-rapport-therapeutics-advancing-rap-219-amid--20m-q4-loss-395052-638772982753484407.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-rapport-therapeutics-advancing-rap-219-amid--20m-q4-loss-395052?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7047","PET.AU"],"gpt_icon":0},{"id":"2516657210","title":"Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516657210","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516657210?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 03:27","pubTimestamp":1741030053,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics  reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography  imaging data in H2 2026.Voyager shares were down nearly 3% in recent trading.Price: 3.97, Change: -0.11, Percent Change: -2.70","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PET.AU","BK4192","BK7047","PET","VYGR"],"gpt_icon":0},{"id":"2510371785","title":"Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371785","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371785?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 21:00","pubTimestamp":1739365200,"startTime":"0","endTime":"0","summary":"Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder. SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited  announces that the publication of its most recent peer-reviewed journal article entitled Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease in Clinical Pharmacology in Drug Development, the journal associated with the American College of Clinical Pharmacology.Actinogen Medical  is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.Actinogen is currently developing its lead compound, Xana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ACW.AU","BK7067","BK4181","LU1169589451.USD","PET","PK","BK7047","PD","BK4218","LU1169590202.USD","PET.AU","BK4023","BK7508","BK4192"],"gpt_icon":0},{"id":"2506224519","title":"Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2506224519","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506224519?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 22:04","pubTimestamp":1738073040,"startTime":"0","endTime":"0","summary":"Two abstracts on Clarity's diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium  2025.An abstract on the COBRA study has also been selected for presentation at the American Urological Association  Annual Meeting 2025.In a subset of participants in the COBRA study who underwent follow-up SOC PSMA PET, 70% of participants had a positive scan on same-day imaging and 90% on next-day imaging using 64Cu-SAR-bisPSMA, compared to 60% of participants using SOC PSMA PET where only same-day imaging is possible. The number of lesions across all participants  identified by 64Cu-SAR-bisPSMA was also higher  than that detected by SOC PET agents . Results indicate that 64Cu-SAR-bisPSMA is able to identify lesions from 29 days to more than 6 months earlier than SOC PSMA agents. Across all participants in the study, histopathology confirmed the presence of prostate cancer in lesions iden","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PET","ON","PET.AU","BK4192","BK4141","SAR.AU","IE00BZ199S13.USD","LU1854103824.USD","BCR","BK7003","LU0724618433.USD","LU0348723411.USD","LU1548497426.USD","BK7061","LU2357305700.SGD","BK4585","LU2298322129.HKD","CU6.AU","BK4512","BK4588","LU1720051017.SGD","BK4135","BK4213","LU1861220033.SGD","SAR","SOC.AU","LU1978683503.SGD","LU0124384867.USD","LU2360107325.USD","AUA.AU","LU1854104046.USD","TGA","BK7047","TGA.AU","LU1720051108.HKD","IE00BD6J9T35.USD","BK7096","LU1861219969.SGD","LU1861215975.USD","SOC","BK7001","LU1861214812.USD"],"gpt_icon":0},{"id":"2505865344","title":"Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505865344","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505865344?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 22:02","pubTimestamp":1737727320,"startTime":"0","endTime":"0","summary":"This milestone builds on Clarity's earlier receipt of an FTD for 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1]. These 2 FTDs enable the Company to accelerate the development of its comprehensive diagnostic program with this product.The FDA's FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs. For 64Cu-SAR-bisPSMA, it provides a number of product development advantages. The designation paves the way for a faster review process once Clarity submits its product approval applications. Additionally, it enables more frequent communication with the FDA, allowing for rapid resolution of queries during development. Furthermore, Clarity can submit completed sections of its application as they are ready, rather than waiting for the entire package to be finished before it can be lodged with the FDA. These benefits would re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CU6.AU","BK7061","BK7096","BK4192","TGA","BK7047","BK4567","BCR","PET.AU","FAST","PET","IE00B5TLWC47.USD","BK4135","BK4213","IE00BFXG0V08.USD","TGA.AU","BK7001","BK4588","SOC.AU","BK4585","SAR","SAR.AU","SOC","IE00BYQQ9H92.USD","BK4104"],"gpt_icon":0},{"id":"2505074824","title":"Why Clarity, Genesis Energy, IGO, and Wesfarmers shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2505074824","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505074824?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 09:29","pubTimestamp":1737682171,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index  is on course to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 8,410.4 points.Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:. The Clarity Pharmaceuticals share price is up 3.5% to $4.20. This follows news that the U.S. Food and Drug Administration  has granted Fast Track Designation  for 64Cu-SAR-bisPSMA. This is for positron emission tomography  imaging of prostate-specific membrane antigen  positive prostate cancer lesions in patients with biochemical recurrence  of prostate cancer following definitive therapy. Clarity executive chair, Dr Alan Taylor, said: \"Receiving the second FTD for 64Cu-SAR-bisPSMA and well within the 60-day period following our application submission, reserved by the U.S. FDA for review, is yet another significant milestone in our bisPSMA program.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/24/why-clarity-genesis-energy-igo-and-wesfarmers-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4550","BK7006","BK7504","TLC.AU","BK4127","IE00B19Z3581.USD","BK4585","BK4516","IGO.AU","BK4192","LU1668664300.SGD","IE00BFXG1179.USD","LU2237443978.SGD","BK7507","LU2237443622.USD","CU6.AU","LU2237438978.USD","BK4588","BK7511","BK4533","BK7047","IE00B19Z3B42.SGD","WES.AU","IE0002270589.USD","LU2237443465.HKD","LU2237443895.HKD","BK7095","GNE.AU","BK4552","BK7041","BK7078","LU1791807156.HKD","LU2237443382.USD","IE0004091025.USD","XJO.AU","IE0004086264.USD","PLS.AU","LU0106831901.USD","IE0034235188.USD","BK7096","PET","PET.AU","BK7506","BK7153","LU2237443549.SGD","BCR","IE00BSNM7G36.USD","BK4504"],"gpt_icon":0},{"id":"2505107139","title":"Guess which ASX 200 biotech stock is jumping 15% on big US FDA news","url":"https://stock-news.laohu8.com/highlight/detail?id=2505107139","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505107139?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 07:58","pubTimestamp":1737676722,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd  shares are ending the week on a high. In early trade, the ASX 200 biotech stock was up as much as 15% to $4.69. Its shares have since pulled back but remain up 3% to $4.19 at the time of writing. Why is this ASX 200 biotech stock jumping?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/24/guess-which-asx-200-biotech-stock-is-jumping-15-on-big-us-fda-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4192","BK7096","PET","PET.AU","CU6.AU","BCR","BK7047"],"gpt_icon":0},{"id":"2504597844","title":"Guess which ASX 200 stock is jumping to record high on big European news","url":"https://stock-news.laohu8.com/highlight/detail?id=2504597844","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504597844?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 07:18","pubTimestamp":1737069517,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd  shares are ending the week on a positive note. In morning trade on Friday, the ASX 200 healthcare stock is up 4.5% to a record high of $27.00. Why is this ASX 200 healthcare stock racing higher?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/17/guess-which-asx-200-stock-is-jumping-to-record-high-on-big-european-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PET","TGA.AU","BK4213","TGA","BK4192","RMS.AU","BK7067","LU1894683348.USD","BK4585","BK4144","BK4588","MAA","BK7001","BK7506","LU2346227817.USD","CMS","BK7047","BK4215","TLX.AU","EEA","PET.AU","LU1894683264.USD","BK4208","LU2637428348.USD","BCR","BK7104","DCP"],"gpt_icon":0},{"id":"2501402404","title":"BRIEF-Phoslock Environmental Tech Announces U.S. Distributor Agreement With Orion Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2501402404","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501402404?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 16:14","pubTimestamp":1736151257,"startTime":"0","endTime":"0","summary":"BRIEF-Phoslock Environmental Tech Announces U.S. Distributor Agreement With Orion CompaniesJan 6 (Reuters) - Phoslock Environmental Technologies Ltd PET.AX:EXCLUSIVE U.S. DISTRIBUTOR AGREEMENT WITH ORION COMPANIESFurther company coverage: PET.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3NZ0KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET.AU","BK7047"],"gpt_icon":0},{"id":"2501470325","title":"Phoslock Environmental Technologies Signs Exclusive US Distributor Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2501470325","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501470325?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 14:02","pubTimestamp":1736143340,"startTime":"0","endTime":"0","summary":"Phoslock Environmental Technologies  entered into an exclusive distributor agreement with The Orion Companies for the distribution of Phoslock products in the US, effective immediately, according to a Monday bourse Australian filing.As per the deal, Orion now has exclusive rights to market, sell, and distribute Phoslock's range of water treatment products across the US market, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PET.AU","BK7047"],"gpt_icon":0},{"id":"2501623422","title":"Exclusive U.S. Distributor Agreement With Orion Companies-Pet.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2501623422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501623422?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 10:01","pubTimestamp":1736128897,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3NZ0KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7047","PET.AU"],"gpt_icon":0},{"id":"2489432650","title":"Investing in a World of Options and Asymmetry","url":"https://stock-news.laohu8.com/highlight/detail?id=2489432650","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489432650?lang=en_us&edition=full_marsco","pubTime":"2024-12-05 20:01","pubTimestamp":1733400077,"startTime":"0","endTime":"0","summary":"“The secret to wealth is finding the asymmetric payoff—small risk, big reward” Nassim Taleb. When this writer first set about a career in finance we were tasked with uncovering how much each ASX energy company was worth, with little more direction than a basic understanding of discounted cash flows and net present values. The task was easy enough; to develop an asset by asset model that delivered a valuation per share, but how do you consider:. Specifically when it comes to oil and gas we were utilising it in the pricing of exploration plays. How does this work?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/investing-in-a-world-of-options-and-asymmetry","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/investing-in-a-world-of-options-and-asymmetry","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["WTC.AU","BK7507","CU6.AU","MTR.AU","IE00B3CCJ633.GBP","MIN","LU0124676726.USD","ORA","BK7508","LU0511384066.AUD","BK4162","OPC.AU","BK7504","MIN.AU","NEU","PET.AU","ORA.AU","TLX","LU2477742899.HKD","AFL","BK7096","AFL.AU","BK7050","LU0472753341.HKD","BK7053","BK7503","IE00B2PGVK34.USD","NEU.AU","PET","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","IMR.AU","ASB","LU0289739343.SGD","MTR","AS","ASB.AU","TLX.AU","BK7067","LU2506952337.HKD","LU2506952410.USD","BOT.AU","BK4211","LU0689626769.HKD","IE00BDGV0183.EUR","BK4133","BK7502","LU0289961442.SGD","BK7115","TAM.AU"],"gpt_icon":0},{"id":"2486339823","title":"First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2486339823","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486339823?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 17:22","pubTimestamp":1732785720,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ --Telix Pharmaceuticals Limited  and Grand Pharmaceutical Group Limited  today announce that afirst patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography  imaging of clear cell renal cell carcinoma . The patient was successfully dosed and imaged at Beijing Cancer Hospital in Beijing, China.Dr David N. Cade, Chief Medical Officer at Telix said, \"Dosing and imaging a first patient in the ZIRCON-CP trial is a significant milestone for Telix and our partner Grand Pharma. We would like to thank Professor Peng Du and his team, as well as the patients who will contribute to this important trial, helping to advance TLX250-CDx towards regulatory filings in Greater China, where there is currently critical unmet medical need.\". As part of Telix's commitment to access to medicine, the Company continues to run an expanded access program  in the U.S.[4], named patient programs  in Europe, and a special acce","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uRsjF.FvOx.8TgpjnSsWgg--~B/aD0xNjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uRsjF.FvOx.8TgpjnSsWgg--~B/aD0xNjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0260c8b822b865d6e9308370c79e16fb"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/first-patient-dosed-phase-iii-092200081.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/first-patient-dosed-phase-iii-092200081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["TGA","XJO.AU","PET.AU","ASX.AU","BK4588","BK4526","PET","BK4134","BK4192","XAO.AU","BK7047","BK4141","TGA.AU","BK4016","CP","LU1261432733.SGD","ASX","TLX.AU","BK7001","XKO.AU","SEC.AU","BK7039","BK7067","TLX","BK4585","BK4139","III","BK4213"],"gpt_icon":0},{"id":"2486335267","title":"Amcor Partners With South Korean Chemical Materials Maker on Sustainable Polyester Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2486335267","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486335267?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 09:42","pubTimestamp":1732758120,"startTime":"0","endTime":"0","summary":"Amcor  partnered with South Korean chemical materials manufacturer Kolon Industries to develop and commercialize sustainable polyester materials for flexible packaging, the packaging company said in a statement Wednesday.The companies will work together in developing chemically recycled polyethylene terephthalate  and polyethylene furanoate  materials, with the aim of integrating 30% post-consumer recycled materials by 2030, according to the statement.PET is commonly used for packaging food and beverages, while PEF is considered a more sustainable alternative.Amcor shares rose nearly 1% in midday trade Thursday.Price : $16.33, Change: $+0.12, Percent Change: +0.74%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4544","BK4125","LU0426412945.USD","LU1043141123.HKD","AUD","BK4192","BK7047","BK7063","PET.AU","PET","LU2238339852.HKD","LU0994945656.USD","MKR.USD.HKCC","LU0426417589.USD","BK4588","LU0345774631.USD","ARKG","BK4585","AMC.AU","MKR.USD.CC"],"gpt_icon":1},{"id":"2485104436","title":"BRIEF-Phoslock Environmental Technologies Served With Group Proceeding Filed In Federal Court Of Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2485104436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485104436?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 09:21","pubTimestamp":1732152090,"startTime":"0","endTime":"0","summary":"Nov 21  - Phoslock Environmental Technologies Ltd   :   * HAS BEEN SERVED WITH A GROUP PROCEEDING FILED IN FEDERAL COURT OF AUSTRALIA   * COMPANY DENIES ANY LIABILITY AND WILL DEFEND PROCEEDINGS   * PROCEEDINGS  BROUGHT ON BEHALF OF PERSONS ACQUIRED INTEREST IN SHARES IN CO BETWEEN 11 OCT 2018 - 17 SEPT 2020   * PROCEEDINGS ALSO ON BEHALF OF PERSONS WHO HAD \"LONG EXPOSURE\" TO PHOSLOCK SHARES Further company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","PET.AU","XAO.AU","XKO.AU","BK7047"],"gpt_icon":0},{"id":"2485795201","title":"Phoslock Environmental Technologies  -Proceedings  Brought on Behalf of Persons Acquired Interest in Shares in Co Between 11 Oct 2018 - 17 Sept 2020","url":"https://stock-news.laohu8.com/highlight/detail?id=2485795201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485795201?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 05:52","pubTimestamp":1732139545,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR195:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7047","PET.AU"],"gpt_icon":0},{"id":"2485179527","title":"Phoslock Environmental Technologies Ltd - Has Been Served With a Group Proceeding Filed in Federal Court of Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2485179527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485179527?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 05:52","pubTimestamp":1732139545,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR195:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PET.AU","BK7047"],"gpt_icon":0},{"id":"2485179522","title":"Phoslock Environmental Technologies Ltd - Company Denies Any Liability and Will Defend Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2485179522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485179522?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 05:52","pubTimestamp":1732139545,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR195:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PET.AU","BK7047"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phoslock.com.au","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0535},{"period":"3month","weight":0.1025},{"period":"6month","weight":0.1269},{"period":"1year","weight":0.2122},{"period":"ytd","weight":0.1051}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Phoslock Environmental Technologies Limited engages in the design, engineering, and project implementation solutions for water related projects and water treatment products. It offers Phoslock, a lanthanum modified bentonite material that removes excess phosphate from water and reduces the growth of harmful algae; Zeolite that is applied to heavily polluted water in order to bind nitrogen; and Bacteria for use in water treatment processes to enhance the quality of water. The company's products are used to clean up lakes, rivers, canals, and drinking water reservoirs. It offers its products through licensees and sales agents in Australia and New Zealand; Europe and the United Kingdom; the United States, Canada, and Brazil; and China. The company was formerly known as Phoslock Water Solutions Limited and changed its name to Phoslock Environmental Technologies Limited in August 2018. Phoslock Water Solutions Limited was founded in 2002 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.009851},{"month":2,"riseRate":0.473684,"avgChangeRate":-0.025245},{"month":3,"riseRate":0.578947,"avgChangeRate":0.072212},{"month":4,"riseRate":0.473684,"avgChangeRate":0.052315},{"month":5,"riseRate":0.315789,"avgChangeRate":-0.038917},{"month":6,"riseRate":0.578947,"avgChangeRate":0.062891},{"month":7,"riseRate":0.368421,"avgChangeRate":-0.026895},{"month":8,"riseRate":0.52381,"avgChangeRate":-0.00117},{"month":9,"riseRate":0.45,"avgChangeRate":0.00272},{"month":10,"riseRate":0.45,"avgChangeRate":0.057782},{"month":11,"riseRate":0.3,"avgChangeRate":-0.02174},{"month":12,"riseRate":0.4,"avgChangeRate":0.005029}],"exchange":"ASX","name":"PHOSLOCK ENVIRONMENTAL TECHN","nameEN":"PHOSLOCK ENVIRONMENTAL TECHN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PHOSLOCK ENVIRONMENTAL TECHN(PET.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PHOSLOCK ENVIRONMENTAL TECHN(PET.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PHOSLOCK ENVIRONMENTAL TECHN,PET.AU,PHOSLOCK ENVIRONMENTAL TECHN股票,PHOSLOCK ENVIRONMENTAL TECHN股票老虎,PHOSLOCK ENVIRONMENTAL TECHN股票老虎国际,PHOSLOCK ENVIRONMENTAL TECHN行情,PHOSLOCK ENVIRONMENTAL TECHN股票行情,PHOSLOCK ENVIRONMENTAL TECHN股价,PHOSLOCK ENVIRONMENTAL TECHN股市,PHOSLOCK ENVIRONMENTAL TECHN股票价格,PHOSLOCK ENVIRONMENTAL TECHN股票交易,PHOSLOCK ENVIRONMENTAL TECHN股票购买,PHOSLOCK ENVIRONMENTAL TECHN股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PHOSLOCK ENVIRONMENTAL TECHN(PET.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PHOSLOCK ENVIRONMENTAL TECHN(PET.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction